NeuroSense Therapeutics L... (NRSN)
1.11
0.04 (3.74%)
At close: Feb 28, 2025, 3:57 PM
1.11
-0.23%
After-hours: Feb 28, 2025, 03:58 PM EST
No 1D chart data available
| Bid | 1.1 |
| Market Cap | 25.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.61M |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -1.89 |
| Analyst | n/a |
| Ask | 1.11 |
| Volume | 57,508 |
| Avg. Volume (20D) | 282,386 |
| Open | 1.11 |
| Previous Close | 1.07 |
| Day's Range | 1.11 - 1.11 |
| 52-Week Range | 0.51 - 2.33 |
| Beta | 1.25 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 9, 2021
Employees 18
Stock Exchange NASDAQ
Ticker Symbol NRSN
Website https://www.neurosense-tx.com
2 months ago
+12.28%
NeuroSense Therapeutics shares are trading higher....
Unlock content with
Pro Subscription
2 months ago
+14.27%
NeuroSense Therapeutics shares are trading higher after the company announced its CEO purchased $5 million worth of ordinary shares in a private placement.
8 months ago · marketwatch.com
This cheap biotech offers investors a play on ALS if trial data continues to impressNeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
